What happened with ALC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Alcon’s larger business supplies hospitals and ambulatory surgery centers with products for eye operations, including cataract and retinal surgery. Surgical consumables generate more revenue than equipment or implantable lenses. Its installed machines support recurring purchases of supplies used in procedures and help sell artificial lenses implanted during cataract surgery. Alcon also provides training and technical support to the professionals using these products.
Its other major business sells contact lenses, including the TOTAL brand, and eye-health products such as Systane artificial tears. Contact lenses account for most of this business’s revenue. Eye-care professionals, retailers and distributors buy and resell these products, with consumers largely paying out of pocket. Professional recommendations influence the initial choice, and contact-lens and lens-care users tend to buy repeatedly.
The business depends on clinicians choosing its products and learning to use them. A considerable part of surgical sales also depends on patients paying extra for premium technologies, so reimbursement rules influence access and demand. Most products require medical-device or pharmaceutical authorization, and Alcon cannot promote them for unapproved uses. Contact lenses require a prescription in many countries.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Alcon’s surgical results also depend on competition with Carl Zeiss Meditec and Hoya, two important eye-surgery rivals missing from this list.
Bausch + Lomb challenges Alcon across contact lenses and eye drops sold to consumers, and replacement lenses, equipment and consumables used by eye surgeons. Its Vision Care and Surgical sales are worth watching for competitive pressure across both sides of Alcon’s business.
Cooper Companies’ CooperVision competes with Alcon to sell contact lenses through eye-care professionals, including lenses for astigmatism and for seeing at multiple distances. Watch its silicone hydrogel lens demand and product launches, as Alcon also relies on customers moving to premium lenses and expanding its astigmatism and multifocal offerings.
Johnson & Johnson competes with Alcon for contact-lens wearers and surgeons choosing lenses implanted during cataract surgery. Its Tecnis premium lens family is a concrete rival to Alcon’s Acrysof family, making Tecnis news more relevant to this rivalry than Johnson & Johnson’s prescription-drug results.
RxSight competes directly with Alcon’s premium cataract lenses by selling eye practices an implanted lens that doctors can adjust after surgery, plus the light-treatment device used to adjust it. Watch ongoing Light Adjustable Lens sales supported by those installed devices for uptake of this alternative to Alcon’s lenses.
Glaukos competes with Alcon to sell eye surgeons products for minimally invasive glaucoma surgery. Watch its iStent family for this surgical rivalry; its broader glaucoma sales also include iDose TR, so that revenue line is not a pure measure of competition with Alcon’s surgery products.
STAAR Surgical competes for the vision-correction patients served by Alcon’s corneal laser equipment, selling implanted lenses that leave the natural lens and corneal tissue in place. Its Implantable Collamer Lens sales, which generate almost all its worldwide revenue, show demand for this alternative to laser surgery.
Sight Sciences competes with Alcon in glaucoma surgery and dry-eye procedures, selling OMNI and SION to surgery centers and hospital outpatient departments, and TearCare to eye-care practices. Watch its Interventional Glaucoma and Interventional Dry Eye sales separately for adoption of competing treatments in these two markets.
Bausch Health competes with Alcon through its approximately 88%-owned Bausch + Lomb business, which sells contact lenses and eye-care products to consumers and surgical products to eye-care providers. Watch the Bausch + Lomb segment rather than Bausch Health’s total revenue: it consolidates the same eye-health business shown separately in this list.
LENSAR remains a cataract-laser competitor to Alcon after their announced merger agreement was terminated, selling its LENSAR and ALLY systems to surgeons, hospitals and surgery centers. Watch ALLY sales and installations for competition in cataract equipment, rather than treating LENSAR as an acquisition awaiting completion.
Alcon depends on supply from Lifecore Biomedical and financed the supplier to secure it; Lifecore makes and sterile-fills injectable drugs and medical-device products for pharmaceutical and biotechnology customers. Watch its ability to meet the Alcon supply agreement’s quality, quantity and delivery requirements, because supplier failures can disrupt Alcon’s sales and profitability.
Bausch + Lomb Corporation earningsBLCO
Bausch + Lomb’s report will show how its Vision Care and Surgical businesses are selling, giving a read on competition in markets it shares with Alcon.
Read Bausch + Lomb’s Vision Care and Surgical sales separately; Bausch Health’s total revenue is not a substitute. Stronger sales in these overlapping eye-care businesses would point to a more competitive rival for Alcon; weaker sales would suggest less pressure, but cannot replace Alcon’s own segment figures.
Glaukos Corporation earningsGKOS
Glaukos’s report will show whether surgeons are adopting its iStent minimally invasive glaucoma surgery products, which compete with Alcon’s surgical business.
Look for iStent sales or adoption; Glaukos’s broader glaucoma revenue also includes iDose TR, so it is not a clean measure of surgical competition. Stronger iStent uptake means more surgeons or centers are choosing a competing option; weaker uptake means less evidence that this alternative is gaining ground.
Lifecore Biomedical, Inc. earningsLFCR
Lifecore’s report will show whether its production and deliveries are reliable; Alcon depends on this supplier, and a disruption could affect product sales.
Watch Lifecore’s comments on production, quality and delivery, especially any indication it cannot meet its supply agreement with Alcon. Reliable output and deliveries support continuity for Alcon’s products; quality problems, shortfalls or delays could disrupt production, raise costs or reduce sales.
RxSight, Inc. earningsRXST
RxSight’s report will show whether eye practices are adopting its adjustable implanted lens, an alternative to Alcon’s premium cataract lenses.
Read Light Adjustable Lens sales alongside installations of the light-treatment devices used to adjust the lenses after surgery. Strength in both would indicate wider practice adoption of an alternative to Alcon’s premium lenses; weaker sales or installations would point to more limited competitive uptake.
Staar Surgical Co earningsSTAA
STAAR’s report will show demand for its implantable Collamer lenses, an alternative to the corneal laser procedures served by Alcon’s equipment.
Watch sales of STAAR’s Implantable Collamer Lens, which generates almost all its worldwide revenue. Stronger sales would mean more vision-correction patients are choosing an implanted lens over corneal laser procedures served by Alcon’s equipment; weaker sales would indicate less demand for that alternative.
Sight Sciences, Inc. earningsSGHT
Sight Sciences’ report will show whether eye-care practices are adopting TearCare dry-eye procedures that compete for demand with Alcon’s ocular-health products.
Focus on Sight Sciences’ Interventional Dry Eye sales, not its separate glaucoma business. Stronger sales would indicate more practices adopting a treatment that competes with Alcon’s ocular-health products for patients and spending; weaker sales would suggest less uptake of that competing option.
Alcon Inc. earningsThis company
Alcon’s report will show whether sales growth in Surgical and Vision Care is adding to each segment’s contribution, or whether costs and pricing pressure are absorbing the gains.
Read sales growth alongside segment contribution margin—the share of segment sales left after the costs included in Alcon’s measure. Growth with a stable or recovering margin says demand and pricing are covering costs; growth with a further margin decline says manufacturing, R&D or competitive pricing is taking a larger share of each sales dollar.
LENSAR, Inc. earningsLNSR
LENSAR’s report will show whether surgeons, hospitals and surgery centers are buying and installing its cataract laser systems, which compete with Alcon’s equipment.
Watch ALLY system sales and installations. The merger agreement with Alcon was terminated, so LENSAR remains a separate competitor. Stronger sales and installations would show it winning more customers in cataract equipment; weaker activity would indicate more limited adoption of this rival system.
The Cooper Companies, Inc. earningsCOO
Cooper Companies’ report will show demand for CooperVision lenses, including toric and multifocal products that compete with Alcon’s contact lenses.
Watch CooperVision demand and launches in silicone hydrogel, toric and multifocal lenses. Stronger demand would mean more wearers and eye-care professionals are choosing products that compete with Alcon’s lenses, intensifying the contest for premium trade-up; weaker demand would point to less pull from this rival.
